Targeted Delivery of Platelet Membrane Modified Extracellular Vesicles into Atherosclerotic Plaque to Regress Atherosclerosis

Qiyu Li,Zheyong Huang,Zhiqing Pang,Qiaozi Wang,Jinfeng Gao,Jing Chen,Zhengmin Wang,Haipeng Tan,Su Li,Fei Xu,Jinxiang Chen,Muyin Liu,Xueyi Weng,Hongbo Yang,Yanan Song,Juying Qian,Junbo Ge
DOI: https://doi.org/10.1016/j.cej.2022.138992
IF: 15.1
2023-01-01
Chemical Engineering Journal
Abstract:Atherosclerosis is a major underlying cause of cardiovascular disease. Although certain success has been achieved in treatment for atherosclerosis, the risk of cardiovascular diseases still remains high. Anti-inflammation therapy was proved to halt atherosclerosis progression, but their clinical application was hindered by the systemic immunosuppressive effect. Since macrophages play a key role in the development of atherosclerosis, targeted delivery of anti-inflammatory therapeutics to lesional macrophages might be an effective therapeutic strategy to resolve localized inflammation while reducing the adverse effects. Mesenchymal stem cells derived extracellular vesicles (MSC-EVs) are believed to possess anti-atherosclerosis effects by reducing inflammation. In this study, we fabricated platelet mimetic MSC-EVs (P-EVs) by decorating EVs with platelets membranes. P-EVs inherited the natural homing ability of platelets to plaques and therapeutic effects of MSC-EVs. When injected into atherosclerotic mice, P-EVs were recruited to injured endothelium, then penetrated into plaques followed with endocytosis by inflammatory macrophages through the interaction between platelet membranes proteins and macrophages surface proteins. Subsequently, P-EVs delivered miRNAs into the cytoplasm of macrophages through lysosomal escape, which attenuated the progression of atherosclerosis eventually by switching the macrophage into anti-inflammatory phenotype, scavenging the overproduced ROS and reducing lipid deposition in lesional macrophages. In general, our study demonstrated the pro-resolving potential of P-EVs for targeted anti-inflammation therapy of atherosclerosis.
What problem does this paper attempt to address?